GlobeNewswire: Achaogen, Inc. Contains the last 10 of 171 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T22:29:52ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/06/06/1865709/0/en/Achaogen-Inc-Announces-Results-of-Auction-for-Substantially-All-Company-Assets.html?f=22&fvtc=4&fvtv=21165Achaogen, Inc. Announces Results of Auction for Substantially All Company Assets2019-06-06T22:46:18Z<![CDATA[SOUTH SAN FRANCISCO, Calif., June 06, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc., a biopharmaceutical company developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, announced today it has reached agreements to sell substantially all of its assets for aggregate cash consideration of approximately $16 million, plus potential royalties and assumption of certain contractual liabilities, subject to negotiation and execution of binding definitive documents and approval of the U.S. Bankruptcy Court for the District of Delaware (the Court):]]>https://www.globenewswire.com/news-release/2019/04/15/1803906/0/en/Achaogen-Plans-for-Near-Term-Sale-Using-Structured-Process-Through-Chapter-11-of-the-U-S-Bankruptcy-Code.html?f=22&fvtc=4&fvtv=21165Achaogen Plans for Near-Term Sale Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code2019-04-15T11:48:22Z<![CDATA[Bidding process and auction projected to conclude June 2019 Bidding process and auction projected to conclude June 2019]]>https://www.globenewswire.com/news-release/2019/03/28/1783626/0/en/Achaogen-Reports-Fourth-Quarter-and-Full-Year-2018-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=21165Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update2019-03-28T20:01:00Z<![CDATA[-- ZEMDRI’s once-daily 30-minute infusion facilitating usage in the outpatient setting ---- Company’s recent restructuring aimed at conserving capital to continue assessment of strategic alternatives --]]>https://www.globenewswire.com/news-release/2019/03/13/1752771/0/en/Achaogen-to-Host-Conference-Call-and-Webcast-of-Fourth-Quarter-and-Year-2018-Financial-Results-on-March-28-2019.html?f=22&fvtc=4&fvtv=21165Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 20192019-03-13T20:01:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., March 13, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it will report its fourth quarter financial results on Thursday, March 28, 2019 after the open of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update. Access to the event can be obtained as follows:]]>https://www.globenewswire.com/news-release/2019/02/21/1739276/0/en/Achaogen-Announces-ZEMDRI-plazomicin-Pivotal-Phase-3-Study-Results-Published-in-the-New-England-Journal-of-Medicine.html?f=22&fvtc=4&fvtv=21165Achaogen Announces ZEMDRI® (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine2019-02-21T13:00:00Z<![CDATA[-- ZEMDRI is the only once-daily aminoglycoside therapy FDA-approved for use in complicated urinary tract infections (cUTI) ---- Treatment with ZEMDRI resulted in a greater than four-fold reduction in relapse of cUTI clinical symptoms compared to meropenem at Day 28 --]]>https://www.globenewswire.com/news-release/2019/02/21/1739286/0/en/Achaogen-Announces-Publication-of-Plazomicin-Phase-3-CARE-Study-Results-in-the-New-England-Journal-of-Medicine.html?f=22&fvtc=4&fvtv=21165Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine2019-02-21T13:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 CARE (Combating Antibiotic Resistant Enterobacteriaceae) study of plazomicin in a Letter to the Editor. In this published study, the efficacy and safety of plazomicin versus colistin was evaluated in patients with serious bloodstream infections or hospital-acquired/ventilator-associated bacterial pneumonia caused by carbapenem-resistant Enterobacteriaceae (CRE). Full study results are published in a Letter to the Editor and Supplementary Appendix in the February 21, 2019 issue of the Journal.]]>https://www.globenewswire.com/news-release/2019/02/20/1738797/0/en/Achaogen-Announces-Closing-of-15-Million-Underwritten-Public-Offering.html?f=22&fvtc=4&fvtv=21165Achaogen Announces Closing of $15 Million Underwritten Public Offering2019-02-20T21:02:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (Nasdaq:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the completion of its previously announced underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its common stock (collectively, the “warrants”).]]>https://www.globenewswire.com/news-release/2019/02/20/1738792/0/en/Achaogen-Announces-Presentations-at-Two-Upcoming-Investor-Healthcare-Conferences.html?f=22&fvtc=4&fvtv=21165Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences2019-02-20T21:01:00Z<![CDATA[-- Leerink February 27, 2019 at 9:30 a.m. ET ---- Cowen March 12, 2019 at 12:00 p.m. ET --]]>https://www.globenewswire.com/news-release/2019/02/15/1726085/0/en/Achaogen-Announces-Pricing-of-15-Million-Underwritten-Public-Offering.html?f=22&fvtc=4&fvtv=21165Achaogen Announces Pricing of $15 Million Underwritten Public Offering2019-02-15T11:11:05Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock and accompanying short-term warrants to purchase up to 15,000,000 shares of its common stock and long-term warrants to purchase up to 15,000,000 shares of its common stock (collectively, the “warrants”). Each share of common stock is being sold together with one short-term warrant to purchase one share of common stock and one long-term warrant to purchase one share of common stock, at a combined price to the public of $1.00 per share of common stock and accompanying warrants, for gross proceeds of $15 million, before deducting underwriting discounts and commissions and offering expenses payable by Achaogen.]]>https://www.globenewswire.com/news-release/2019/02/14/1725807/0/en/Achaogen-Announces-Proposed-Public-Offering-of-Common-Stock.html?f=22&fvtc=4&fvtv=21165Achaogen Announces Proposed Public Offering of Common Stock2019-02-14T21:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ: AKAO), a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant (MDR) gram-negative infections, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares to be sold in the offering will be offered by Achaogen. In addition, Achaogen expects to grant the underwriter of the offering a 30-day option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.]]>